Liquidia Technologies, Inc. Stock News

MORRISVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the first quarter ended March 31, 2025. The company will also host a webcast at 8:30 a.m. ET on May 8, 2025 to discuss its financial results and provide a corporat...

Liquidia Corporation's legal victory clears the path for Yutrepia's FDA approval and market entry, targeting PAH and PH-ILD, with final approval expected by May 24, 2025. Yutrepia's competitive advantages include a patient-friendly inhaler, lower cost structure, and strong clinical profile, positioning it to capture market share from United Therapeutics' Tyvaso DPI. Liquidia is financially prep...

MORRISVILLE, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Judge Kelly of the U.S. District Court for the District of Columbia (District Court) dismissed, without prejudice, the cross-claim filed by United Therapeutics (UTHR) that sought ...

MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quarter 2025 financial results on Thursday, May 8, 2025.

ENDI Corp's shares rose significantly, driven by a substantial increase in AUM and a value-unlocking transaction, suggesting further upside potential. Finch Therapeutics awaits a post-trial decision that could significantly impact its share value, with a minimum award level already set. Nam Tai Property secured significant financing and sold a non-core property above appraisal value, indicating...

Liquidia Corporation will provide an overview of the company's business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.

Liquidia Corporation will provide an overview of the company's business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.

The U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder.